Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

TYVASO helped lower the risk of PH-ILD getting worse by 39% in a 16 week clinical study.
TYVASO helped lower the risk of PH-ILD getting worse by 39% in a 16 week clinical study.

REDUCING THE RISK OF PH-ILD GETTING WORSE

TYVASO has been shown to reduce disease worsening

During the 16-week study, TYVASO helped lower the risk of PH-ILD getting worse by 39%.

Learn more about taking TYVASO.

NOW APPROVED—TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern